Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Business In Brief

This article was originally published in The Tan Sheet

Executive Summary

Pfizer: Consumer Healthcare sales of $741 mil., up 14%, in the second quarter, were driven by the continued strong performance of Listerine mouthwash and uptake of Listerine PocketPaks in international markets. The rollout of FreshBurst Listerine line extensions and the weaker dollar also helped edge up revenues. Sales of PocketPaks in the U.S. slowed and the firm's Benadryl and Sudafed line were hurt by the presence of OTC Claritin on the market, Pfizer notes...
Advertisement

Related Content

Martek acquisition
Martek acquisition
Martek acquisition
Martek Production Capacity Expected To Reach $200 Mil.-$250 Mil. in 2004
Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions
Weight-Loss Segment Future Uncertain With PPA Actions, Ephedra Questions

Topics

Advertisement
UsernamePublicRestriction

Register

PS095729

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel